New drug raises enzyme levels but shows no clear benefit over standard care for TTP

People with thrombotic thrombocytopenic purpura, a rare blood disorder, often struggle to find effective treatments. A large review looked at a new drug called recombinant ADAMTS13. This medicine is designed to raise levels of a specific enzyme that helps break down dangerous blood clots. The review combined data from two clinical trials involving 129 patients with either congenital or acquired forms of the disease. The goal was to see if this new drug worked better than standard therapy or a placebo. The study found that the new drug did significantly increase enzyme activity. This was a clear success in the lab. However, the main goal was to prevent acute TTP events, which are the dangerous clotting episodes that define the illness. The review found no significant difference in preventing these events compared to standard care. Patients taking the new drug also had fewer cases of hives, a common side effect. Other side events were similar between groups. The researchers noted that the overall certainty of these findings is moderate to low. This is because the data came from only two trials. Larger studies are needed to confirm if this drug truly helps patients live longer or feel better. Until then, doctors should not assume the new drug offers clear clinical benefits over existing options.